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THE ROLE of anticalcineurin agents, cyclosporine A(CyA) and tacrolimus (TRC), in the development of
chronic allograft nephropathy (CAN) and subsequently
in long-term graft survival seems to be of major impor-
tance owing to their nephrotoxic effect.1 Unfortunately,
no successful alternatives are available to date. Sirolimus
has shown a similar efficacy to CyA when used alone with
respect to graft rejection rates and short-term graft
survival, either in combination with steroids and azathio-
prine or with steroids and mofetil mycophenolate
(MMF).2,3 With the objective of a low rejection rate and
the minimization of CyA nephrotoxicity a multicenter,
randomized, phase III trial at 3 years is currently ongoing
in 57 centers in Europe, Canada, and Australia with a
total of 525 patients enrolled. This trial compares two
arms, a control arm (A) using CyA, fixed doses of
sirolimus, and steroids, and a study arm (B) with CyA,
concentration-controlled sirolimus, and steroids with sus-
pension of CyA at 3 months’ postransplant. Partial
results of this study at 1 year have shown a low rejection
rate in both arms with a significantly better graft function
at 1 year in group B.4 Nevertheless, the pathological
effects of CyA withdrawal have not yet been analyzed. In
this report we present the results of graft biopsy evalua-
tions at 1 year in a subgroup of patients.
MATERIALS AND METHODS
Graft biopsies at the moment of transplantation and at 1-year
posttransplant were analyzed in the subgroup of patients included
in Spain and Portugal. All patients with a functioning graft at 1 year
and the two biopsies performed were considered (70 patients and
140 biopsies, corresponding to 35 patients in every group). Biopsies
were evaluated locally according to the Banff’95 classification and
chronicity changes (ah, eg, ci, ct, and cv) were computed.5 A
chronicity score (CS) was calculated as the sum of the last four
items. These findings as well as renal function at 1 year were
compared between the two groups. We considered the existence of
progression of chronicity lesions when Banff encoding for every
lesion was higher in the 1-year biopsy than in the transplant (basal)
biopsy. When it was equal or lower it was considered as no
progression. The CS was analyzed in the same way. It was
considered the percentage of patients with progression of chronic-
ity findings in every group (individual lesions and CS) and com-
pared using the chi square test.
RESULTS
Among the 140 biopsies evaluated, 83 (59%) were consid-
ered as adequate (more than 6 glomeruli and at least 1
artery), 31 (22%) were considered as marginal, and the
remaining 24 (19%) were not satisfactory. One-year plasma
creatinine level was 1.88 mg/dL in group A and 1.48 mg/dL
in group B (P  .05). Progression of lesions was as follows
(percentage of patients in group A and B, respectively): cg
18.5% vs 19.2% (n  53; P  NS); ci 61.3% vs 56.7% (n 
61; P  NS); ct 51.6% vs 50% (n  61; P  NS); cv 32% vs
31.6% (n  44; P  NS); ah 36.7% vs 32.3% (n  61; P 
NS). When the CS was considered it was observed progress-
ing in 64% of cases in group A and in only 47.4% of cases
in group B (n  44), although this difference was not
statistically significant.
CONCLUSIONS
Early CyA withdrawal in a regimen including sirolimus is
followed by an improvement in graft function as well as in
the pathological parameters that define chronic allograft
nephropathy. This reduced severity of chronic lesions when
CyA is eliminated might be attributed to a decreased
chronic nephrotoxicity without an increase in the immuno-
logical response against the allograft. Nevertheless, the
absence of a central pathological evaluation should serve to
consider these results with caution.
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